Lv5
1290 积分 2023-11-09 加入
Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma Patients
5小时前
已完结
The Role of 1q Abnormalities in Multiple Myeloma: Genomic Insights, Clinical Implications, and Therapeutic Challenges
7小时前
待确认
Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis
1天前
待确认
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
2天前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
17天前
已完结
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
17天前
已完结
Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant
19天前
已完结
Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study
29天前
已完结
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
29天前
已完结
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML
1个月前
已完结
皖公网安备34019202002308
